|
X4 Pharmaceuticals ، Inc. (xfor) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
X4 Pharmaceuticals, Inc. (XFOR) Bundle
استكشف الآفاق المالية لـ X4 Pharmaceuticals ، Inc. (XFOR) مع حاسبة DCF سهلة الاستخدام! أدخل افتراضاتك المتعلقة بالنمو والهوامش والمصروفات لحساب القيمة الجوهرية لـ X4 Pharmaceuticals ، Inc. (XFOR) وتحسين استراتيجية الاستثمار الخاصة بك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | 3.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | -100 | 0 | 0 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -51.7 | -58.1 | -85.1 | -87.6 | -107.1 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | -1935.5 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | .7 | 1.2 | 1.9 | 2.0 | .4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 41 | 100 | 100 | 100 | 88.2 | 88.2 | 88.2 | 88.2 | 88.2 |
| EBIT | -52.4 | -59.3 | -87.0 | -89.6 | -107.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | -1976.5 | 100 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 126.2 | 78.7 | 81.8 | 121.7 | 114.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 2.0 | .9 | .7 | 1.2 | .6 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 30.57 | 100 | 100 | 100 | 86.11 | 86.11 | 86.11 | 86.11 | 86.11 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 0 | 100 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 2.1 | 3.1 | 4.3 | 7.8 | 8.9 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 104.8 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | -1.4 | -.6 | -.1 | -.1 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | -45.4 | 100 | 100 | 100 | -9.08 | -9.08 | -9.08 | -9.08 | -9.08 |
| Tax Rate, % | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 | -0.07715973 |
| EBITAT | -56.1 | -59.4 | -87.0 | -89.6 | -107.6 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -55.6 | -57.4 | -84.4 | -84.6 | -105.5 | -8.4 | .0 | .0 | .0 | .0 |
| WACC, % | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 | 7.21 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -7.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -8 | |||||||||
| Net Debt | -41 | |||||||||
| Equity Value | 33 | |||||||||
| Diluted Shares Outstanding, MM | 178 | |||||||||
| Equity Value Per Share | 0.19 |
What You Will Get
- Comprehensive XFOR Financials: Access to historical and projected data for precise valuation.
- Customizable Parameters: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess X4 Pharmaceuticals' future performance.
- User-Friendly Layout: Designed for professionals but easy for newcomers to navigate.
Key Features
- Customizable Drug Development Parameters: Adjust key metrics such as market potential, clinical trial costs, and projected timelines.
- Instant Valuation Models: Automatically generates intrinsic value, NPV, and other financial metrics in real-time.
- Industry-Leading Precision: Incorporates X4 Pharmaceuticals' actual performance data for accurate valuation results.
- Effortless Scenario Testing: Evaluate various hypotheses and analyze results with ease.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation frameworks from the ground up.
How It Works
- Download: Obtain the comprehensive Excel file featuring X4 Pharmaceuticals, Inc.'s (XFOR) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment choices.
Why Choose X4 Pharmaceuticals, Inc. (XFOR)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of seasoned professionals committed to advancing patient care.
- Robust Pipeline: A diverse range of drug candidates in various stages of development.
- Strong Partnerships: Collaborations with leading organizations to enhance research and development.
- Commitment to Quality: Adherence to the highest standards in pharmaceutical manufacturing and testing.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling X4 Pharmaceuticals stock (XFOR).
- Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to X4 Pharmaceuticals (XFOR).
- Consultants: Deliver professional valuation insights on X4 Pharmaceuticals (XFOR) to clients quickly and accurately.
- Business Owners: Understand how biopharmaceutical companies like X4 Pharmaceuticals (XFOR) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to X4 Pharmaceuticals (XFOR).
What the Template Contains
- Preloaded XFOR Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.